Evidence map›Paper›PMID 30298279›Full record

ReviewPharmacoEconomics2019

Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.

Lindsay Claxton, Joanne O'Connor, Nerys Woolacott, Kath Wright, Robert Hodgson

Erratum issued Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in PharmacoEconomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07026669 (A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07026669 recruitingnot on this mapstarted 2025, after this paper: background citation

A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer: A Prospective, Non-interventional Study

Typeobservational_patient_registrySponsorCancer Institute and Hospital, Chinese Academy of Medical SciencesRan2025 to 2027Enrolled40ConditionsSmall Cell Lung Cancer
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Lindsay ClaxtonCentre for Reviews and Dissemination, University of York, York, YO10 5DD, UK. lindsay.claxton@york.ac.uk.ORCID 0000-0002-1795-7568
Joanne O'ConnorCentre for Reviews and Dissemination, University of York, York, YO10 5DD, UK.
Nerys WoolacottCentre for Reviews and Dissemination, University of York, York, YO10 5DD, UK.
Kath WrightCentre for Reviews and Dissemination, University of York, York, YO10 5DD, UK.
Robert HodgsonCentre for Reviews and Dissemination, University of York, York, YO10 5DD, UK.
University of York · GBKleijnen Systematic Reviews (United Kingdom) · GB

Funding

Department of Health 16/134/13
6 · The paper itself

Abstract

The National Institute for Health and Care Excellence (NICE) invited the company that manufactures ceritinib (Zykadia

Indexed as

Anaplastic Lymphoma KinaseAntineoplastic AgentsCarcinoma, Non-Small-Cell LungClinical Trials, Phase III as TopicCost-Benefit AnalysisHumansLung NeoplasmsProgression-Free SurvivalPyrimidinesQuality-Adjusted Life YearsRandomized Controlled Trials as TopicSulfonesTechnology Assessment, BiomedicalALK protein, humanAnaplastic Lymphoma KinaseAntineoplastic AgentsceritinibPyrimidinesSulfones

Identifiers

PMID30298279
OpenAlexW2897321755

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.